Rick Whiles, MD
Internal Medicine · Bristol, TNNPI 1013911874
Payments from drug & device makers
Across 560 payments — averaging $2638.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.2M
- Eli Lilly$264K
- E.r. Squibb & Sons, L.L.C.$5K
- Astrazeneca UK Limited$3K
- Novo Nordisk AS$2K
- Novo Nordisk$1K
- plus $3K from 33 others
Across 12 payments — averaging $202.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
- AbbVie$974
What the payments were for
- Travel & lodging$5,18749%
- Food & beverage$5,36951%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,477,281 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $59,897 |
| JardianceEmpagliflozin | 52 | $47,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $39,686 |
| RybelsusSemaglutide | 11 | $31,578 |
| MounjaroTirzepatide | 26 | $30,982 |
| OzempicSemaglutide | 24 | $26,976 |
| FarxigaDapagliflozin Propanediol | 26 | $25,785 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,253 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,938 |
| JanuviaSitagliptin Phosphate | 25 | $8,567 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $5,813 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $5,581 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,069 |
| SynthroidLevothyroxine Sodium | 52 | $4,886 |
| Duloxetine Hcl | 145 | $4,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,198,832 | $59,89753 claims |
| Novo NordiskRybelsus, Ozempic | $1,092 | $58,55435 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $687 | $56,00879 claims |
| Boehringer IngelheimJardiance, Synjardy | $15 | $53,41463 claims |
| Lilly USA, LLCMounjaro | $164 | $30,98226 claims |
| AstraZenecaFarxiga | $164 | $25,78526 claims |
| MerckJanuvia | $58 | $8,56725 claims |
| AbbVieSynthroid | $635 | $4,88652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Bristol
- Bernard GrunstraBristol$6.4M
- Donald QuinnBristol$868K
- Stephanie PowellBristol$170K
- Shelby OldsBristol$89K
- Mark McKenzieChattanooga$11.9M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- John AndersonNashville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.